REPLIGEN NAMES VP OF PRODUCT DEVELOPMENTRepligen Corp. of Cambridge, Mass., has appointed Howard L.Levine, Ph.D., to the new position of vice president of productdevelopment. Levine had been director of the pilot plant atXoma Corp., where he was responsible for the scale-up andproduction of E5. Repligen (NASDAQ:RGEN) develops andmanufactures health care biochemical products, primarily inthe areas of AIDS, cancer and inflammation.

In addition, Michael Nemzek has joined the company as vicepresident of sales. Tropix develops, manufactures and marketschemiluminescent reagents and related products.

Ann F. Hanham, Ph.D., former manager of clinical studies atBecton Dickinson Immunocytometry Systems, has beenappointed director of medical affairs at Celtrix LaboratoriesInc. Palo Alto, Calif.-based Celtrix (NASDAQ:CTRX) isdeveloping therapeutics based on a family of naturallyoccurring proteins that regulate cell function.

DynaGen Inc. of Cambridge, Mass., appointed Dr. F. HowardSchneider senior vice president of technology. He will beresponsible for commercialization of the company'sbiomaterials and diagnostics technologies. Schneider waspartner and senior vice president of Bogart Delafield Ferrier, ahealth-care consulting firm. DynaGen (NASDAQ:DYGN) developsdiagnostic and therapeutic products for human and animalhealth care.

Ronald W. Edinger has been named to the newly createdposition of vice president and chief financial officer at MatrixPharmaceutical Inc. of Menlo Park, Calif. Matrix is a privatelyheld company developing therapeutics based on proprietarydrug delivery technology for use against cancer and difficult-to-treat skin diseases. Edinger was president and chiefexecutive officer at Covalent Systems Corp., a softwarecompany.

U.S. Bioscience Inc. of West Conshohocken, Pa., has namedKenneth R. Lynn vice president, general counsel and corporatesecretary. Lynn had worked in the legal division at MarionMerrell Dow. U.S. Bioscience (ASE:UBS) develops drugs forcancer and allied diseases.

Genentech Inc. of South San Francisco, Calif., has promoted Dr.Hugh David Niall from director of developmental biology tovice president.

Synbiotics Corp. (NASDAQ:SBIO) of San Diego said Daniel F. Cainhas resigned from its board of directors and Robert L.Widerkehr, president of Synbiotics Animal Health and seniorvice president of Synbiotics Corp., has been appointed to theboard.

Gilles Pajot has been appointed president of PharmaciaBiosystems, a unit of Procordia AB of Sweden. Pajot, who ispresident of Kabi Pharmacia's French marketing, will remain atKabi parallel with his new position. He replaces Rolf Classon,who resigned to join another company. Pharmacia Biosystems,located in of Piscataway, N.J. supplies chemicals andinstruments for biotechnology and health care applications.

(c) 1997 American Health Consultants. All rights reserved.